. Author manuscript; available in PMC: 2019 Mar 20.

Published in final edited form as: Bioorg Med Chem. 2010 Mar 31;18(10):3481–3493. doi: 10.1016/j.bmc.2010.03.070

Table 1.

Inhibitory activities toward mitochondrial complex I^a of the described verticipyrone analogues

Compound	IC₅₀^b
	NADH oxidase (nM)	NADH-ubiquinone (Q1) oxidoreductase (nM)
1	64.9 ± 1.7	230.9 ± 5.7
12	13,590 ± 500	16,410 ± 240
13	14,740 ± 460	19,020 ± 450
14	10,670 ± 690	13,300 ± 1050
15	52.6 ± 1.0	151.1 ± 4.6
16	45.9 ± 1.7	133.1 ± 3.2
17	43.2 ± 2.2	126.2 ± 2.2
18	55.0 ± 1.7	180.2 ± 8.8
19	50.8 ± 2.3	145.4 ± 5.9
20	47.5 ± 3.4	135.3 ± 4.6
21	4290 ± 130	1250 ± 96
22	>20,000	>25,000
28	72.5 ± 1.2	257.1 ± 13.1
29	218.9 ± 8.5	595 ± 35.8
30	35.9 ± 1.1	101.6 ± 4.0
Rotenone	4.36 ± 0.07	Nt

Performed using bovine heart submitochondrial particles (SMP).

The molar concentration required for half-maximal inhibition of the control. Values are mean ± SD of three independent experiments. NADH-ubiquinone oxidoreductase was determined with ubiquinone 1 (Q₁) as the ubiquinone substrate. Control activity was approximately 0.75–0.9 μmol min⁻¹ mg⁻¹ for NADH oxidase and 0.65–0.75 lmol min⁻¹ mg⁻¹ for NADH-ubiquinone oxidoreductase. Nt, not determined.